Cambridge, UK, July 31st 2007 — Prosarix Ltd., the drug discovery company specialising in computational screening and design, and ChemOvation Ltd, a leading provider of medicinal chemistry services, today announced a co-development and licensing agreement relating to the further development of a compound series against an undisclosed GPCR target discovered using the Prosarix technology.
